When is IBRX's latest earnings report released?
The most recent financial report for Immunitybio, inc. (IBRX) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating IBRX's short-term business performance and financial health. For the latest updates on IBRX's earnings releases, visit this page regularly.
What is the operating profit of IBRX?
According to the latest financial report, Immunitybio, inc. (IBRX) reported an Operating Profit of -64.68M with an Operating Margin of -168.95% this period, representing a growth of 6.8% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is IBRX's revenue growth?
In the latest financial report, Immunitybio, inc. (IBRX) announced revenue of 38.29M, with a Year-Over-Year growth rate of 406.95%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does IBRX have?
As of the end of the reporting period, Immunitybio, inc. (IBRX) had total debt of 842.69M, with a debt ratio of 1.68. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does IBRX have?
At the end of the period, Immunitybio, inc. (IBRX) held Total Cash and Cash Equivalents of 88.33M, accounting for 0.18 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does IBRX go with three margins increasing?
In the latest report, Immunitybio, inc. (IBRX) did not achieve the “three margins increasing” benchmark, with a gross margin of 99%%, operating margin of -168.95%%, and net margin of -161.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess IBRX's profit trajectory and future growth potential.
Is IBRX's EPS continuing to grow?
According to the past four quarterly reports, Immunitybio, inc. (IBRX)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.06. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of IBRX?
Immunitybio, inc. (IBRX)'s Free Cash Flow (FCF) for the period is -71.65M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 17.88% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of IBRX?
The latest valuation data shows Immunitybio, inc. (IBRX) has a Price-To-Earnings (PE) ratio of -28.76 and a Price/Earnings-To-Growth (PEG) ratio of 0.67. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.
